Biotech | January 04, 2022
USFDA grants ILiAD Biotechnologies Fast Track Designation for pertussis vaccine
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
Partnering to build biosynthesis processes and a pharmaceutical production platform
The Health ID will allow users to connect with different healthcare providers and enable a consent-based sharing of personal health records
The glucometer connects to one’s smartphone and provides actionable diagnostic information
With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction1
Innovative market development collaboration also signed, expanding the availability of select Novartis oncology products in regions across China currently not covered by Novartis
The NMPA approval is based on the positive data of GEMSTONE-302 study, a multi-center, randomized, double-blind, phase III study that evaluated the efficacy and safety of Cejemly or placebo in combination with chemotherapy in first-line stage IV NSCLC patients
The surgery was helmed by Prof. Dr. Vishwanath Pai, Sr. Consultant, Department of Minimally Invasive Surgery, Prashanth Hospitals, Velachery
The medicine is the first and only oral MET inhibitor to receive CHMP positive opinion in Europe for adult patients with advanced NSCLC harbouring alterations leading to METex14 skipping
The proposed scheme to include low-income NRIs under Ayushman Bharat (PM-JAY) would ensure life-long coverage for each individual along with their spouses
Subscribe To Our Newsletter & Stay Updated
